Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 5/20 | 0.45 |
| ▸ | RAB9A | P51151 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30861605 | 0.83 | MEN1 (0.52) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19NPC1 | |
| SCHEMBL76069 | 0.83 | SMN1; SMN2 (0.49) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19NPC1 | |
| SCHEMBL29394827 | 0.83 | SMN1; SMN2 (0.49) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19NPC1 | |
| SCHEMBL17839910 | 0.83 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19NPC1 | |
| SCHEMBL17973539 | 0.82 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19NPC1 | |
| SCHEMBL18507798 | 0.81 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19NPC1 | |
| SCHEMBL17391071 | 0.81 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19NPC1 | |
| SCHEMBL10284047 | 0.79 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19NPC1 | |
| SCHEMBL4576394 | 0.79 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19NPC1 | |
| SCHEMBL757021 | 0.77 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4622991-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | Janssen Pharmaceutica NV (BE) | 2025-10-01 | — | — | EP | claimed |
| EP-4619408-A1 | THE SYNTHESIS OF OMAPATRILAT | Endothelium Scanning Nanotechnology Limited (AU) | 2025-09-24 | — | — | EP | claimed |
| US-12215114-B2 | Processes and intermediates for producing diazaspiro lactam compounds | NAUREX INC. (US) | 2025-02-04 | — | — | US | claimed |
| EP-4472948-A2 | NICOTINATE AND NICOTINAMIDE RIBOSIDE-BASED COMPOUNDS AND DERIVATIVES THEREOF | New Frontier Bio, Inc. (US) | 2024-12-11 | — | — | EP | claimed |
| CN-118613472-A | Nicotinamide ester and nicotinamide riboside-based compounds and derivatives thereof | 新前沿生物公司 | 2024-09-06 | — | — | CN | claimed |
| EP-3986400-B1 | PROCESSES AND INTERMEDIATES FOR PRODUCING DIAZASPIRO LACTAM COMPOUNDS | NAUREX INC (US) | 2024-08-21 | — | — | EP | claimed |
| US-20240269640-A1 | METHODS AND COMPOSITIONS FOR LARGE-SCALE CONJUGATABLE POLYMER AND PROTEIN SYNTHESIS | Ligandal, Inc. | 2024-08-15 | — | — | US | claimed |
| WO-2024110477-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | JANSSEN PHARMACEUTICA NV (BE) | 2024-05-30 | — | — | WO | claimed |
| WO-2024103123-A1 | THE SYNTHESIS OF OMAPATRILAT | Endothelium Scanning Nanotechnology Limited (AU) | 2024-05-23 | — | — | WO | claimed |
| EP-4329931-A1 | METHODS AND COMPOSITIONS FOR LARGE-SCALE CONJUGATABLE POLYMER AND PROTEIN SYNTHESIS | Ligandal, Inc. (US) | 2024-03-06 | — | — | EP | claimed |
| US-9308479-B2 | Cross-linked carbon nanotube networks | THE BIO NANO CENTRE LIMITED (GB) | 2016-04-12 | — | — | US | claimed |
| EP-2872500-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF DABIGATRAN ETEXILATE MESYLATE AND ITS INTERMEDIATES THEREOF | Rao, Davuluri Ramamohan (IN) | 2015-05-20 | — | — | EP | claimed |
| US-20150122800-A1 | CROSS-LINKED GRAPHENE NETWORKS | KING ABDULAZIZ UNIVERSITY (SA) | 2015-05-07 | — | — | US | claimed |
| EP-2822893-A2 | CROSS-LINKED GRAPHENE NETWORKS | The Bio Nano Centre Limited (GB) | 2015-01-14 | — | — | EP | claimed |
| WO-2014009966-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF DABIGATRAN ETEXILATE MESYLATE AND ITS INTERMEDIATES THEREOF | RAO DAVULURI RAMAMOHAN (IN) | 2014-01-16 | — | — | WO | claimed |
| EP-2665552-A2 | CROSS-LINKED CARBON NANOTUBE NETWORKS | Bio Nano Consulting (GB) | 2013-11-27 | — | — | EP | claimed |
| WO-2013132259-A1 | GRAPHENE AND GRAPHENE OXIDE AEROGELS/XEROGELS FOR CO2 CAPTURE | BIO NANO CONSULTING (GB) | 2013-09-12 | — | — | WO | claimed |
| WO-2013132260-A2 | CROSS-LINKED GRAPHENE NETWORKS | BIO NANO CONSULTING (GB) | 2013-09-12 | — | — | WO | claimed |
| WO-2013093520-A2 | HEATABLE CARBON NANOTUBE AEROGELS, XEROGELS AND GELS | BIO NANO CONSULTING (GB) | 2013-06-27 | — | — | WO | claimed |
| WO-2012098345-A2 | CROSS-LINKED CARBON NANOTUBE NETWORKS | BIO NANO CONSULTING (GB) | 2012-07-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12215114-B2 | Processes and intermediates for producing diazaspiro lactam compounds | DDO, DHPS, PGLS | ALDH1A1 3004/4885SMN1; SMN2 2645/4885CYP1A2 1138/4885 |
| US-20150122800-A1 | CROSS-LINKED GRAPHENE NETWORKS | MACF1, MTCL3, GIGYF2 | ALDH1A1 2306/4885SMN1; SMN2 4416/4885CYP1A2 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.